Drug intelligence / Profile preview

X-22

Development stage: Phase 2
Lead developer: 22nd Century Group
Administration: Inhalation

Overview

X-22 is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes. Developed by 22nd Century Group, Inc. and its subsidiary Hercules Pharmaceuticals LLC, it is designed as a prescription smoking cessation aid. Its therapeutic approach involves significantly reducing the nicotine content delivered to the user compared to conventional cigarettes, thereby aiming to decrease nicotine dependence.

Other names: X-22 Smoking Cessation ProductX22 Smoking Cessation ProductX 22 Smoking Cessation Product

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on X-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-22.

Explore the full profile